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Summary
  Radiation therapy represents an important aspect of breast cancer treatment. Application of irradiation reduces the 
incidence of local disease recurrence and improves overall survival of breast cancer patients. Studies have shown that adju-
vant irradiation after breast-conserving surgery has the same result as a mastectomy, so adjuvant radiotherapy enables 
sparing surgery in breast cancer patients. We will review the mechanisms, indications and methods of the whole breast 
 irradiation, as a standard approach to the treatment. The main directions and controversies of today’s research will be 
shown, primarily the introduction of hypofractionation, i.e. distribution of high daily doses of irradiation in a shorter over-
all period of treatment, as well as the application of partial breast irradiation, i.e. irradiation of a part of the breast instead of 
postoperative irradiation of the whole breast. Further molecular analysis of tumor biology will lead to the new prognostic 
and predictive parameters, and thus to the further personalization in the fi eld of breast cancer radiotherapy.
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ZRAČENJE U LIJEČENJU RAKA DOJKE
Sažetak
Radioterapija je koristna u liječenju raka dojke. Smanjuje pojavu lokalnog recidiva i produljuje preživljenje. Studije su 
pokazale da adjuvantno zračenje nakon poštednog kirurškog zahvata ima iste rezultate kao mastektomija i omogućuje 
 primjenu poštedne kirurgije. Kao standardni pristup liječenja prikazani su mehanizmi, indikacije i metode zračenja cijele 
dojke. Razmatrani su smjerovi i kontroverze istraživanja, hipofrakcioniranje, (primjene većih dnevnih doza u kraćem 
 ukupnom vremenskom razdoblju) i djelomično zračenje dojke, umjesto standardnog poslijeoperacijskog zračenja cijele 
 dojke. Dodatne molekularne analize biologije tumora dovest će do novih prognostičkih i prediktivnih čimbenika, a time i do 
dodatne personalizacije u području radioterapije raka dojke.
KLJUČNE RIJEČI: rak dojke, radioterapija, poštedna operacija dojke
INTRODUCTION
The role of radiation therapy in the treatment 
of breast cancer has long been known important. 
Adjuvant radiation therapy reduces the likelihood 
of local recurrence after surgery and increases the 
overall survival of patients (1,2). The importance of 
radiation therapy in the treatment of breast cancer 
may be the most obvious in the fact that without 
this form of adjuvant treatment, breast sparing sur-
gery in many cases would not be possible. Specifi -
cally, it has been shown that the percentage of local 
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recurrence after treatment with a combination of 
breast sparing surgery and adjuvant radiation is 
equal to the percentage of recurrence after mastec-
tomy (1). So adjuvant radiotherapy after breast 
sparing surgery is today an essential component of 
treatment for early stage breast cancer. In locally 
advanced disease, adjuvant radiation therapy also 
signifi cantly increases local disease control and 
survival of patients, especially in patients with tu-
mor metastases in axillary lymph nodes (2). In pa-
tients with metastatic disease radiation therapy is 
an essential part of palliative treatment.
1. General principles of radiation therapy
Irradiation is in the most cases carried out by 
the high energy photons produced in linear accel-
erators. Linear accelerators are devices that essen-
tially function as complex cathode ray tubes - a 
part of the accelerator called an electron gun, fi res 
electrons into a strong electromagnetic fi eld inside 
the tube where they accelerate to high speeds, and 
so accelerated electrons hit the target in and phe-
nomenon called “breaking radiation” or releasing 
high energy X-rays (MeV). Then, the resulting X-
rays are formed by the collimator into the desired 
(default) bundles, and turning the head unit di-
rected in the desired direction.
Going through the tissue of the patient, X-
rays or photons interact with the matt er, produc-
ing diff erent eff ects. In simple terms, megavolt 
photon radiation will, like billiard balls, hit the 
electron of an atom, handing him some of his en-
ergy suffi  cient to release an electron, and continue 
its journey in a changed direction (so-called, 
Compton eff ect) with further interaction until it 
consumes all of his remaining energy. So formed 
ion, and the released electron are also involved in 
a number of interactions. The radiation of energy 
greater than 1.02 MeV leads to the eff ect known as 
“pairing”. Specifi cally, in contact with the electric 
fi eld of the atomic nucleus photon decays into a 
electron-positron pair, whereby the electron con-
tinues its path causing further ionization, and the 
positron, which is unstable, connects with another 
electron, thus creating a new pair of photons, each 
having the energy of 0.51 MeV.
The consequences of these reactions are the 
ionizations and creation of unstable molecules 
and free radicals within the cells of the organism. 
This results in a number of physical and chemical 
reactions that lead to the damages of all cell struc-
tures, including proteins, lipids and deoxyribo-
nucleic acid (DNA). The key damage are the dou-
ble- strand DNA breaks, inhibition of cell replica-
tion and reproduction.
The higher dose of radiation means increased 
destrucion of tumor cells, but unfortunately also 
healthy cells and tissues can be damaged. The 
goal of irradiation is to destroy the maximum 
number of tumor cells, but to spare the normal tis-
sue as much as possible. It is therefore necessary 
in the radiation radiation planning to defi ne the 
target tumor tissue more precisely and to develop 
such a radiation plan that will allow maximum 
sparing of the surrounding healthy tissue.
In order to achieve the above objectives, in 
addition to the total dose of radiation, it is ex-
tremely important to determine the ratio of the 
total dose and the time in which the patient will 
receive this dose. This division of the total irradia-
tion dose into daily doses that the patient receives 
during a specifi c time is called “fractionation.” 
Fractionation is the best way to use the diff erent 
nature of the tumor and healthy cells, or diff erent 
periods that these cells need to recover from radia-
tion damage. 
In the breast cancer, the most applied is the 
standard fractionation, or the daily irradiation 
dose of 2 Gy (Greys) fi ve days a week for fi ve 
weeks, to a total dose of 50 Gy.
In certain cases it is necessary upon the com-
pletion of the whole breast irradiation, to apply an 
additional dose of irradiation only to the tumor 
bed, which is called a “boost” dose.
2. Radiation therapy after neoadjuvant treatment
In patients who receive neoadjuvant system-
ic therapy before surgical treatment (eg, chemo-
therapy, hormonal therapy, anti-HER-2 therapy) 
histopathological fi ndings after surgery may vary 
from an unchanged tumor state (meaning tumor 
resistance to the conducted chemotherapy), to the 
complete clinical tumor regression after chemo-
therapy. According to the current guidelines, de-
cisions related to postoperative radiotherapy 
should be based on the initial clinical tumor char-
acteristics, regardless of the tumor response to 
systemic treatment, including tumors with com-




3.  Adjuvant radiation therapy 
after breast-conserving surgery
The approach to adjuvant radiotherapy after 
breast sparing surgery primarily depends on the 
histological type of tumor. So, the indications for 
this type of treatment diff er according to whether 
it is lobular carcinoma in situ, ductal carcinoma in 
situ or invasive breast cancer. 
Lobular carcinoma in situ (LCIS) 
Since the risk of invasive cancer after a breast-
conserving procedure for LCIS is signifi cantly 
low, and the tumors have favorable histology and 
are successfully treated, the recommended treat-
ment is breast conserving surgery followed by 
monitoring - mammography annually with clini-
cal exams once or twice a year. NCCN doesn’t rec-
ommend adjuvant radiation therapy in the case of 
lobular carcinoma in situ (3).
Ductal carcinoma in situ (DCIS) (stage 0, Tis, N0, M0)
The decision of the primary treatment of duc-
tal carcinoma in situ (DCIS) primarily depends on 
the characteristics of the tumor histology. Al-
though mastectomy provides maximum local 
control of the disease, in the case of limited dis-
ease (one quadrant), equal treatment results have 
been shown in patients who underwent mastec-
tomy, and in patients who underwent breast con-
serving surgery followed by adjuvant radiothera-
py (4,5,6). In patients with large multicentric tu-
mors, the treatment of choice is the mastectomy 
without the dissection of the lymph nodes.
Several major prospective randomized stud-
ies have shown that adjuvant radiotherapy in duc-
tal carcinoma in situ reduces the appearance of 
local recurrence by 50 % (both invasive and non-
invasive), and the risk of recurrence is increased 
proportionately to the time after an operation 
(4,5,6). There is an eff ort to identify a subgroup of 
patients with a very low risk DCIS where adjuvant 
radiotherapy may not be needed, but the results 
are controversial. According to some authors this 
pertains to tumors less than 1 cm in size, low 
grade, with negative operating edges, positive 
hormone receptors, and patient age greater than 
60 yr. (6). Probably only the analysis of the biology 
of DCIS will bring more information about the 
need for additional adjuvant treatment of this dis-
ease. There are ongoing studies of gene expres-
sions using Oncotype DX DCIS recurrence score, 
thereby in combination with the other histological 
characteristics of the tumor a group of patients 
with DCIS could be marked as extremely low risk, 
who would not need adjuvant radiotherapy after 
surgery.
The defi nition of negative operating edge in 
the case of DCIS is still under discussion. A few 
years ago a consensus was reached that the mar-
gin greater than 10 mm is considered negative, but 
less than 1mm positive, but the consensus has not 
yet been reached when it comes to values between 
these two. According to some authors, the greater 
the margin, the lower the incidence of local recur-
rence. On the other hand, resection edge of less 
than 1 mm in the area of the fi broglandular border 
(near the skin or thoracic wall), if a re-excision 
cannot be performed, may represent an indication 
for a greater “boost” dose of radiation to the de-
scribed area. According to the recently published 
joint guidelines of the American Society of Surgi-
cal Oncology and the American Society for Radio-
therapy and Clinical Oncology (ASO, ASTRO, 
ASCO) based on a comprehensive analysis of 20 
studies with 7883 patients, 2 mm negative operat-
ing margins are considered adequate with DCIS ( 
with the implementation of postoperative radio-
therapy) (Morro M et al., J Clin Oncol, published 
on line, Aug 2015). If the operating edge is less 
than 2 mm, individual clinical decisions are re-
quired about the need for re-excision. Unlike 
DCIS, in invasive cancer a negative operating edge 
is now considered if there is no ink on the tumor 
margin of the histopathological tumor sample.
Invasive cancer (stages I, IIA, IIB, or T3, N1, M0)
In the case of invasive cancer, adjuvant radio-
therapy is in the most cases necessary after breast-
conserving procedures. Radiation therapy actual-
ly allows breast-conserving surgery because it has 
been shown that a combination of both has the 
same therapeutic eff ect as a mastectomy. Of 
course, histopathological and biological features 
of the tumor determine the signifi cance of radio-
therapy. Overall it was shown that radiotherapy 
signifi cantly reduces local recurrence and prolon-
ges overall survival of patients. Long term (15 
years) monitoring of patients in the EBCTGC 
studies have shown that radiation therapy reduc-
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es the incidence of local recurrence in the breast 
for approximately 30 % (from 35 % to 19 %), and 
signifi cantly reduces mortality from breast cancer 
(7). It is believed that the adjuvant radiotherapy 
may be omitt ed in women older than 70 years 
with hormone-dependent tumor stage I (negative 
lymph nodes, T1 tumor). A study comparing two 
groups of patients of these characteristics, one of 
which received adjuvant hormonal treatment and 
radiation, and the second only hormonal treat-
ment, showed no statistically signifi cant diff er-
ence between the groups in overall survival, sur-
vival till recurrence or need for mastectomy (8).
If patients received adjuvant chemotherapy 
containing anthracyclines or taxanes, radiothera-
py treatment can only begin after the end of che-
motherapy. There is no clear evidence whether to 
start fi rst with adjuvant radiotherapy, but accord-
ing to the guidelines, the treatment begins with 
adjuvant chemotherapy followed by radiotherapy 
(9,10). To the current guidelines radiation therapy 
can be combined with anti-HER-2 therapy (trastu-
zumab) and with hormone therapy.
4. Adjuvant radiation therapy after mastectomy
According to current guidelines, radiation af-
ter mastectomy is indicated in patients with 4 or 
more positive axillary lymph nodes, but it should 
be considered also in patients with 1-3 positive 
lymph nodes. Specifi cally, it has been shown that 
prophylactic radiation of the thoracic wall signifi -
cantly reduces the likelihood of locoregional re-
currence in patients with 4 or more positive lymph 
nodes (11). Although consensus has not been 
reached when it comes to 1-3 positive lymph 
nodes, the recommendations are that patients 
with 1-3 aff ected lymph nodes and tumors larger 
than 5 cm, or in the case of a positive resecting 
edge, be sure to consider adjuvant radiotherapy of 
the chest, supra - and infraclavicular lymphatic 
drainage, as well as possibly radiation of the ipsi-
lateral internal mammary chain lymph nodes (cat-
egory 2B). In the case of negative lymph nodes, 
thoracic irradiation is recommended in patients 
with tumors larger than 5 cm (T3) or positive re-
section edge (12).It is also recommended in these 
patients to consider radiation of the ipsilateral su-
praclavicular lymph nodes and ipsilateral internal 
mammary nodes. Radiation therapy after mastec-
tomy is not recommended in patients with tumors 
smaller than 5 cm, negative lymph nodes and neg-
ative resecting margins.
Nevertheless, retrospective analysis showed 
the reduction of recurrence risk in patients with 
negative lymph nodes, but with high-risk factors 
such as a close resection margin, tumors greater 
than or equal to 2 cm, pre-menopausal status and 
lymphovascular invasion (13). Another study 
showed an increased risk of local recurrence in pa-
tients with negative nodes and triple negative dis-
ease, with tumors less than or equal to 5 cm (14). 
Hopefully, future molecular analysis of the tumor 
biology, will lead to the new prognostic and pre-
dictive parameters and specify the indications for 
radiotherapy.
5. Local lymphatic drainage radiotherapy
Axillary lymph nodes are traditionally divid-
ed into three fl oors. The fi rst fl oor consists of 
lymph nodes located caudal to the lower limit of 
the great pectoral muscle, the second fl oor is lo-
cated posterior to the small pectoral muscles, and 
the third fl oor is located medial and cranial of the 
pectoral muscles. Rott er nodes are often described 
as nodes that are located between the large and 
small pectoral muscle. The literature states that for 
an adequate assessment of the status of lymph 
nodes, the dissection of the fi rst and second fl oor 
axillary lymph nodes is necessary, containing at 
least ten histologically analyzed lymph nodes 
(15,16). In the event of clinically positive nodes in 
the second fl oor, the third fl oors axillary dissec-
tion is necessary.
In the case of four or more positive lymph 
nodes, the lymph drainage radiation, which in-
cludes the supraclavicular, infraclavicular, inter-
nal mammary lymph nodes, and axillary lymph 
nodes that are at risk, is absolutely indicated. Ra-
diation of these regions is also recommended in 
the case where there are 1-3 positive nodes. Also, 
one should consider the radiation of one or more 
areas of the lymphatic drainage in patients who 
underwent mastectomy with T3 tumors (greater 
than 5 cm) or positive margins (3).
Whenever possible, assessment of the status 
of the lymph nodes is done on the basis of histo-
pathological analysis of the guard lymph node 
(sentinel node biopsy). In case of negative fi nd-
ings in the guard node, the tumor is classifi ed as 
N0. However, the controversy remains over the 
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issue of axillary dissection in case of positive fi nd-
ings in the guard node. ACOSOG 0011 study com-
pared a group of patients who made only guard 
node dissection with a group which had axillary 
dissection. Patients had tumors stage T1/T2 and 
less than 3 positive nodes guards, and both groups 
were treated with breast conserving surgery and 
adjuvant radiotherapy of the whole breast. In this 
study there were no signifi cant diff erences be-
tween the two groups, not in the percentage of lo-
cal recurrence, survival to a recurrence, nor in 
overall survival (17). Based on these results, axil-
lary dissection is not indicated in patients with 
less than three positive guard lymph nodes, tumor 
stage T1 or T2, who were not treated with neoad-
juvant, but conserving surgery and radiotherapy 
of the whole breast. AMAROS randomized study 
showed that in patients with T1 and T2 tumors 
and positive sentinel lymph nodes, radiation ther-
apy of the axillary region has the same eff ect as 
dissection (18). However, in this study the rate of 
axillary recurrence were in both groups less than 
expected, which to some extent aff ects the inter-
pretation of results.
Regional lymph drainage radiotherapy in the 
case of isolated tumor cells (metastasis less than 
0.2 mm) and micrometastases in the sentinel node 
(metastasis size 0.2-2 mm) is subject to debate. Still 
there are not enough studies related to this issue. 
Several studies have shown a connection between 
micrometastases in the sentinel lymph node with 
an increased number of relapses and reduced sur-
vival (19,20,21). On the other hand, several retro-
spective studies point to a similar prognosis of 
patients with the presence of isolated tumor cells 
or micrometastases in sentinel lymph nodes of pa-
tients with a negative sentinel with emphasis that 
patients with positive sentinel were more often 
treated adjuvant, radiotherapy or systemic thera-
py (22,23).
Due to this, when deciding on regional lymph 
drainage radiation in the case of micrometastases 
in the guard lymph node, att ention should be 
payed to the histological features of the primary 
tumor. If these characteristics require adjuvant 
systemic chemotherapy (example, if there is a risk 
of systemic disease scatt ering), it is possible to 
conclude that the same applies to the nature of the 
disease in the lymph node. However, in making 
clinical decisions, it is necessary for each patient to 
individually weigh out the potential benefi t for ra-
diation therapy, in terms of the possible side ef-
fects that it brings (24).
6. Radiation techniques and target volumes
When there is an indication for radiation, the 
clinical target volumes for breast cancer are the 
breast or the thoracic wall and the areas of the re-
gional lymphatic drainage. In order for the radia-
tion to be properly implemented, it is necessary to 
achieve several conditions: daily reproducible po-
sition of the patient during radiation, dose homo-
geneity in the target volume and the maximum 
protection of the surrounding tissues and organs.
During radiation planning techniques known 
as three-dimensional conformal radiotherapy 
(3D-CRT) and intensity modulated radiotherapy 
form (IMRT) are used. Radiation planning is per-
formed on the CT simulator. The patient is placed 
on a table, in a special rack for the breast, which 
ensures immobilization in the corresponding po-
sition, with the hands above the head, usually at 
an angle of 90 degrees to the axis of the body, thus 
ensuring the accuracy and reproducibility of the 
process. After the simulation, the development of 
the treatment plan begins, for which special soft-
ware programs are used. The most commonly 
implemented form is intensity modulated radio-
therapy - forward intensity modulated radiother-
apy (fIMRT) in which the distribution of the dose 
is achieved with main bundles, and improves by 
adding additional conformaly formed bundles 
(25). The radiation is carried out by a linear accel-
erator (external radiation), and in certain cases can 
be implemented as internal radiation or brachy-
therapy, where various radioactive sources (main-
ly cesium and iridium) are used. Brachytherapy 
can be interstitial and intracavitary, depending on 
how the radioactive source in the breast tissue is 
inserted, or into the cavity formed upon tumorec-
tomy, what word will be something later.
Radiation protocols
In most cases in the radiotherapy of breast 
cancer we use the so called standard protocol which 
involves the whole breast external radiation with or 
without regional lymph drainage area of  a daily 
dose of 2 Gy, fi ve days a week for fi ve weeks, to a 
total dose of 50 Gy. However, in recent years more 
and more protocols are being tested which use 
higher individual doses of radiation in a shorter 
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overall period of time and with a reduction in the 
total dose of radiation (hypofractionation).
Several randomized clinical trials (26,27,28,29) 
comparing hypofractionation whole breast radia-
tion protocols (39-42.9 Gy, 2.6-3-3 Gy per fraction) 
with standard protocols 50 Gy in 25 fractions per 2 
Gy. Data collected in the ten-year follow-up peri-
od in the START study, as well as in the Canadian 
study showed that the local disease control, as 
well as the aesthetic eff ect was similar in applica-
tion protocols 42.5 Gy in 16 fractions over 3.2 
weeks, compared with 50 Gy in 25 fractions over 
fi ve weeks (29). START study also showed in the 
case of the simplifi ed protocol a signifi cantly low-
er incidence of certain side eff ects associated with 
normal breast tissue such as the contraction of the 
breast, the formation of telangiectasia, and edema 
of the breast (30). In the case of radiotherapy of the 
whole breast, NCCN recommends a dose of 45-50 
Gy in 23-25 fractions or 40-42.5 Gy in 15-16 frac-
tions, with preference for the latt er protocol (data 
from the START study, convenience Protocol).
ASTRO (American Society for Radiation On-
cology) guidelines do not recommend hypofrac-
tionation in patients younger than 50 years, pa-
tients after mastectomy, in cases where it is neces-
sary to radiate the lymphatic drainage, if there is 
an indication for the “boost”, and after adjuvant 
chemotherapy. Recommendation for now is only 
for patients aged 50 and older, tumor pT1 and 2, 
N0 after conservative breast surgery who did not 
receive chemotherapy.
In France, in older patients who for various 
reasons have problems with daily radiation , they 
routinely use a special scheme of 32.5 Gy in 5 
weekly fractions per 6.5 Gy. Study Institute Curie 
compared a group of patients treated by the above 
mentioned scheme with the group treated by stan-
dard fractionation. Although the results showed a 
similar local control, overall survival and disease-
free survival, given that there were great diff er-
ences between the groups (the number of partici-
pants, age of the participants ...) and that they 
haven’t thoroughly studied the toxicity, are sub-
ject to criticism (31). Currently there is an ongoing 
international randomized Phase II study SKA-
GEN that examines the role of hypofractionated 
Protocol in the radiation of the lymphatic drain-
age in cases of early breast cancer.
In patients with increased risk (younger than 
50 g, high tumor grade, positive resection edge), 
after a breast-conserving procedure and upon 
completion of adjuvant radiotherapy of the whole 
breast, the “boost” radiation of the tumor bed is 
indicated (32). “Boost” doses may be technically 
implemented with the help of photon or electron 
beams, or by using brachytherapy. Usual doses 
are 10-16 Gy in 2 Gy fractions.
Accelerated partial breast radiation
In the last few decades the approach to the 
treatment of localized breast cancer has dramati-
cally changed. Breast sparing surgery in combina-
tion with adjuvant radiotherapy is the gold stan-
dard in the treatment of women with breast  cancer 
early stage today. The above mentioned hypofrac-
tionated protocols where the entire breast is radi-
ated in a shorter period of time and with higher 
daily doses, is a promising and relatively new ap-
proach in breast cancer radiotherapy. Accelerated 
partial breast radiation , which involves targeted 
radiation of only part of the breast, or places where 
the tumor was, is being tested as an alternative to 
whole breast radiation. It can be implemented by 
external radiation, brachytherapy, or in the form 
of intraoperative radiotherapy. Advantages of 
partial irradiation of the breast are: shorter dura-
tion of treatment, more focused radiation therapy, 
the possibility of giving high doses of radiation to 
a small volume and in shorter time periods. How-
ever, the follow-up of patients included in studies 
that have examined this form of treatment is rela-
tively short, so we still cannot certainly say which 
subgroup of patients we can truly radiate adju-
vant only part of the breast instead of the whole 
breast, or what are the long-term results of treat-
ment in terms of reduction in local recurrence and 
quality of life. Additional investigations are being 
conducted.
Brachytherapy
This type of treatment is carried out with the 
help of radioactive sources that are placed in the 
breast tissue. Interstitial brachytherapy is carried 
out by using a catheter inserted into the breast tis-
sue. This method is poorly distributed mostly be-
cause of the complicated procedure of inserting 
interstitial catheters. The appliecation is limited to 
a limited number of patients with early stage 
breast cancer (33).
Intracavitary brachytherapy in breast cancer 
is performed by inserting a catheter with an infl at-
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able balloon into a post-operative cavity. The best 
known applicator is MammoSite®, and its advan-
tage is its easy use, compared to a complicated 
procedure of interstitial catheter insertion. After 
MammoSite® there have been developments and 
other, more advanced models of this type of 
brachytherapy, the multi-lumen balloon, which is 
easier to adjust to the shape of post-operative cav-
ity, such as for example Contura®. SAVI® took 
the whole story a step forward with the introduc-
tion of peripheral catheters that surround the cen-
tral, thus achieving higher dose fl exibility.
  Intracavitary brachytherapy can be carried 
out intraoperatively, so-called “open-cavity” tech-
nique, or as a separate procedure (“closed-cavity”) 
up to ten weeks postoperatively. If applied post-
operatively, it is inserted either through the post-
operative scar, or through a separate incision. Af-
ter insertion, the balloon is infl ated with sterile 
saline to 4-5 cm in diameter with the addition of 
contrast. On CT images the balloon is designated 
as the target volume with the addition of a margin 
of 1cm. The usual dose of radiation is 34 Gy one 
time. The method is also used for the application 
of the “boost” dose to the tumor bed, after the 
whole breast radiation. Smith and colleagues ret-
rospectively analyzed a group of patients who 
were treated by this method and have noticed that 
these patients were more likely to subsequently 
undergo mastectomy compared with patients 
who were treated with the standard protocol (33). 
Some studies have shown that accelerated partial 
breast radiotherapy can have in a number of cases 
side eff ects such as breast pain, fat necrosis and rib 
fractures (34).
Intraoperative radiotherapy (IORT)
Partial breast irradiation can be carried out 
via mobile accelerators (eg. Novac7® device that 
generates an electronic fi eld strength 4-12 MeV, 
Intrabeam® that generates photons of low energy 
to 50 kV). Several studies have investigated and 
are still investigating the eff ect of intraoperative 
radiation therapy in a single dose of 20, or 21 Gy to 
the tumorectomy site, compared to the classical 
adjuvant whole breast radiotherapy (35,36). Moni-
toring of patients who are included in this study is 
still ongoing. One of the major drawbacks of intra-
operative radiotherapy is that the radiation is ap-
plies immediately after surgery, when there are 
still no defi nitive pathologic fi ndings. The study 
Target-A (Targeted Intraoperative Radiotherapy) 
used low energy of 50 kV over a spherical applica-
tor located in the tumor beds in low-risk patients. 
A single dose of 20 Gy was applied. After 5-year 
monitoring it has been shown that in 15% of pa-
tients, whole breast radiation had to be added 
based on the defi nitive histological fi ndings. The 
emergence of local recurrence was 3 % in the pa-
tients treated with IORT, to 1 % in the control 
group who received standard protocol whole 
breast radiation (35). The single-institution ELIOT 
study (Milan) electrons were used for intraopera-
tive radiotherapy. A single dose of 21 Gy intraop-
eratively was administered. 5-year monitoring of 
patients showed that the group treated with IORT 
had statistically signifi cant more local recurrence 
(5 %), compared to 1 % in the control group who 
had whole breast radiation 50 Gy in 25 fractions. It 
was concluded that the method should be ap-
proached with caution, we need careful selection 
of patients and an intensive program of quality 
control in this method of radiotherapy (36). Zhang 
and his colleagues recently published the results 
of a meta-analysis of 5415 patients who were treat-
ed with intraoperative radiotherapy which 
showed signifi cantly more local recurrence in this 
group of patients than in patients treated with ra-
diation of the whole breast standard protocol (37). 
The results of these studies of intraoperative ra-
diotherapy for breast cancer still require further 
follow-up of patients, and considering the possi-
ble poorer treatment results in terms of increased 
incidence of local recurrence and caution when 
applying (37,38).
Since the research on accelerated partial 
breast radiation therapy is still in progress, for 
now it is not recommended as a standard treat-
ment for breast cancer. ASTRO guidelines suggest 
a possible application of partial breast irradiation 
using brachytherapy or external irradiation in se-
lected patients with early stage breast cancer, 
where the results of partial radiation could be 
comparable with the results of standard radio-
therapy of the whole breast (39). The candidates 
for adjuvant accelerated partial breast radiation 
would be women aged 60 or older, negative for 
BRCA mutation 1 and 2, with unifocal hormone 
dependent ductal invasive carcinoma stage T1N0, 
or similar tumor favorable histology. Also, it 
should not be invasive ductal component or LCIS, 
Lib Oncol. 2016;44(2–3):21–30
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as neither positive resection edge. To the tumor 
bed 34 Gy in 10 fractions is applied twice daily 
when using brachytherapy, or 38.5 Gy in 10 frac-
tions twice daily in case of external radiation. 
Some studies have shown that the ASTRO-know 
guidelines may not be good enough predicting in-
creased incidence of local recurrence in the same 
breast after this method of radiation (40,41). Sev-
eral studies related to this issue are currently in 
progress. One of them is the large study NSABP 
B39 / RTOG 0413 which included 4300 patients, 
where they examined partial breast irradiation by 
external radiation at a dose of 34 Gy in 10 frac-
tions, compared to the standard whole breast ir-
radiation 50 Gy in 25 fractions. There is an ongo-
ing IMPORT LOW study in the UK, with the in-
volved 2018 patients, where they examined partial 
breast irradiation in relation to the radiation of the 
whole breast external radiation using IMRT tech-
nique. Therefore, the NCCN guidelines for now 
recommend accelerated partial breast radiothera-
py primarily in the context of clinical trials. Sure-
ly, further molecular analysis of tumor biology 
will lead to the new prognostic and predictive pa-
rameters, and thus to the further personalization 
in the fi eld of breast cancer radiotherapy. 
7. Radiation side eff ects
The side eff ects of radiotherapy are divided 
into early and late. Early side eff ects occur during 
radiation and can last for a month upon the com-
pletion of radiation. They occur in the majority of 
patients during the second or third week of radia-
tion as a consequence of damage to the epidermis. 
They are manifested by erythema of the skin in the 
radiated areas and dry and moist desquamation. 
They’re harmless and temporary.
Late complications usually occur 3-6 months 
upon completion of radiation. These side eff ects 
are partly irreversible as a consequence of damage 
to the heart, lungs, blood and lymph vessels, the 
subcutaneous tissues, bones, and nerves. Heart 
failure is the only late complication that needs to 
be taken into account when sett ing the indications 
for radiation. Other late complications that should 
be mentioned are coronary artery damage result-
ing in ischemic heart disease, brachial plexus in-
jury, radiation pneumonitis and pulmonary fi bro-
sis, arm swelling, fractured ribs, and, rarely, the 
occurrence of secondary malignant tumors. Using 
conformal radiotherapy and maximum protection 
of healthy tissue signifi cantly reduces the possibil-
ity of side eff ects and complications of breast can-
cer radiotherapy (42).
8. Palliative radiotherapy
The purpose of palliative radiation primarily 
is to eliminate / reduce the symptoms of advanced 
disease and, consequently, improve the quality of 
life of patients. The most common indications for 
this type of radiotherapy are pain and / or bleed-
ing caused by advanced disease, neurological dis-
orders caused by the presence of tumor trans-
plants in the central nervous system, spinal cord 
compression, or pathological bone fracture. In 
breast cancer patients, palliative radiotherapy is 
usually applied to the bone, brain, ocular and ret-
robulbar metastasis. Also, palliative radiotherapy 
can be applied, in advanced cases of inoperable 
tumors alone or in combination with a systemic 
treatment. (42,43).
Planning palliative radiation is done on the 
CT simulator, and usually carried out by means of 
two opposite fi elds. The total dose and fraction-
ation depends on the radiation area and type of 
tumor. In doing so, we must take into account the 
previously irradiated regions of the body in order 
to avoid the application of excessive doses of ra-
diation to the same area and thus prevent unwant-
ed toxicity.
In the case of pain due to bone metastases, in 
most cases a single radiation dose of 8 Gy is rec-
ommended. For areas such as the cervical spine, 
the involvement of meninges, or, in the case of 
large nodal tumor weight, the recommended dose 
of 20 Gy distributed in fi ve daily fractions per 4 
Gy. In the case of large ulcerated and necrotic tu-
mors, especially in patients of poor general condi-
tion, it is advisable to apply 36 Gy divided into 6 
weekly fractions per 6 Gy (42). 
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